

Regulatory Story

[Go to market news section](#)

NMC Health Plc - NMC UPDATE REGARDING INDEPENDENT REVIEW
Released 08:31 12-Mar-2020

RNS Number : 9023F
NMC Health Plc
12 March 2020

FOR IMMEDIATE RELEASE

12 March 2020

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION NO. 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

**NMC HEALTH PLC
("NMC")**

Update regarding independent review

NMC announced on 17 January 2020 that the Independent Review Committee of the Board of NMC (the "Committee") had retained the law firm Glaser Weil LLP which then engaged Mr Louis Freeh, former Federal Judge and FBI Director, and his firm Freeh Group International Solutions, LLC (together the "Review Advisers"), in each case to advise and assist the Committee in relation to its review into allegations raised in recent reports by short seller Muddy Waters and certain other third parties.

The Review Advisers have informed the Committee that they have discovered evidence leading to suspected fraudulent behaviour in relation to some elements of NMC's previous financial activities. NMC is fully committed to investigating these activities and has notified the relevant authorities in the UK and UAE to determine what action they also consider to be appropriate.

Moelis, PwC and Allen & Overy continue to support the Company, including in its discussions with lenders and to assist in providing transparency with respect to its financial position.

Whilst these various investigations are ongoing, NMC remains fully focused on the provision of its healthcare services in all communities in which it operates, and on its business performance, as well as safeguarding its operational liquidity to continue funding existing operations throughout its various subsidiaries.

The individual responsible for releasing this announcement is Simon Watkins, Group Company Secretary.

Enquiries:

NMC Health plc

Simon Watkins, Group Company Secretary
Asjad Yahya, Head of Investor Relations

+44 (0) 203 205 7313
+971 (0) 56 219 0975

FTI Consulting

Edward Bridges / Simon Conway / Victoria Foster Mitchell
Shane Dolan

+44 (0)20 3727 1000
+971 (0)4 437 2100

About NMC Health

NMC is one of the leading private healthcare operators in the Gulf Cooperation Council ("GCC") with an international network of multi-specialty inpatient and outpatient clinics and hospitals, specialized maternity and fertility clinics, and long-term care homes hospitals across nineteen countries. NMC also ranks as one of the top two in-vitro fertilisation operators globally. The NMC Health group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursuing a selective international expansion programme since 2016, NMC has total capacity of 2,207 licensed beds across its network. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. The NMC Health group treated over 7.5 million patients in 2018. The NMC Health group is also a leading UAE supplier of products and consumables coming from healthcare related products. NMC reported revenues of US\$2.1 billion for the year ended 31 December 2018.

In April 2012, NMC was listed on the Premium Segment of the London Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDJTMPTMTTBMPM

CLOSE

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

regarding independent review - RNS